523 Gene test identifies 67% of patients for Targeted Therapy or Immunotherapy
Bernard A. Fox, Adjunct Professor in the Department of Molecular Microbiology and Immunology at the Knight Cancer Institute, shared a post by American Society of Clinical Oncology (ASCO) on LinkedIn:
“WOW!!
Imagine if there was a test Cancer patients could take that had a 67% chance of changing their treatment and the potential to increase their survival?
The report from Brian Piening & colleagues Earle A. Chiles Research Institute/Providence Cancer Institute + Illumina & Microsoft Co-pilot found their in-house developed 523 gene test identified 67% of patients were candidates for guideline-recommended targeted therapy or immunotherapy!!
“Clinical Outcomes for CGP-Tested Patients – Across all tumor types, patients treated with biomarker-guided TT or IO show significant improvements in overall survival versus chemotherapy (Figs 4A and 4B).”
CONCLUSIONS of the JCO publication/American Society of Clinical Oncology(ASCO).
“Overall, these data represent a major shift in standard clinical practice toward molecularly guided treatments (targeted and immunotherapies) over conventional systemic chemotherapy. As guidelines continue to evolve and more precision therapeutics gain approval, we expect this gap to continue to widen.”
Quoting American Society of Clinical Oncology (ASCO)‘s post:
“A new study at a large U.S. health system has found that routine comprehensive genomic profiling, or CGP, at the time of diagnosis can greatly increase the use of precision therapies among patients with advanced cancer and improve their overall survival.
Among more than 3,200 patients with advanced cancer whose biopsies were tested using an in-house CGP assay, two-thirds had “actionable” biomarkers, meaning they were candidates for guideline-recommended targeted therapy or immunotherapy or for clinical trials testing precision therapies. “That was pretty striking,” said co-author Dr. Brian Piening, of the Earle A. Chiles Research Institute at the Providence Cancer Institute. “The majority of patients could potentially be treated with a therapy that was not just chemo.”
ASCO Daily News has more on this new study, recently published as part of a special series in JCO Oncology Practice.
Click here to read.”
Bernard A. Fox is the Co-Founder, President, and CEO of UbiVac. He is an Adjunct Professor in the Department of Molecular Microbiology and Immunology, at the Knight Cancer Institute. He is also a Member of Board of Directors at Oregon Bioscience Association.In 2012, Dr. Fox received the Harder Family Endowed Chair for Cancer Research in recognition of his efforts in translational cancer therapy.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023